Clinical Trials for Uterine Fibroids Recruiting Now: Letrozole Study in California, Minnesota, Mississippi and North Carolina

Uterine fibroids (also called leiomyomas or myomas) are non-cancerous growths in the uterus that affect many women during their reproductive years. They can cause heavy menstrual bleeding, pelvic pain or pressure, urinary or bowel issues, and fertility challenges. While many women manage symptoms with medication or surgery, clinical trials are exploring new options like aromatase inhibitors to reduce fibroid size and symptoms without immediate surgery.

One actively recruiting Phase 4 study is testing letrozole (an aromatase inhibitor) versus placebo for uterine leiomyoma symptoms and size.

Actively Recruiting Trial: Prescription of Letrozole for Uterine Myoma (PLUM Study)

NCT ID: NCT06143631
Sponsor: University of California, San Francisco
Phase: 4
Status: RECRUITING
Key Locations (United States):

• Los Angeles, California (University of California, Los Angeles)
• San Francisco, California (University of California, San Francisco)
• Rochester, Minnesota (Mayo Clinic)
• Jackson, Mississippi (University of Mississippi Medical Center)
• Durham, North Carolina (Duke University)

Study Design Highlights:

• Randomized, double-blinded, 2-arm, parallel-group, placebo-controlled trial.
• Compares letrozole (2.5 mg) versus placebo on leiomyoma-related symptoms, quality of life, and changes in leiomyoma and uterine size.
• Participants are premenopausal women with symptomatic uterine fibroids.
• Duration: Up to the study completion date of 2027-12-13 (start date 2024-07-24).
• Primary focus: symptom burden (using UFS-QOL SSS score) and fibroid/uterine measurements via imaging.

Key Eligibility Criteria (summary):

• Women aged 21 to 53 years (premenopausal focus).
• Uterine leiomyomata confirmed on pelvic imaging (ultrasound or MRI) within the last 24 months.
• Symptoms such as heavy uterine bleeding, pelvic pressure, urinary/bowel issues, or pain for at least 3 months.
• Moderate symptom burden (UFS-QOL SSS score of 30 or higher).
• Has had a menstrual period in the past 3 months.
• Willing to use non-hormonal or barrier contraception during the study.

Exclusions include: Very large fibroids (≥10 cm or uterine size ≥16 cm), recent treatments (surgery, GnRH agonists, etc. within 12 weeks), current pregnancy/lactation/planning pregnancy, severe anemia, osteoporosis, certain liver conditions, or other contraindications. Full criteria are determined by the study team.

This trial aims to assess whether letrozole can effectively reduce fibroid-related symptoms and size compared to placebo, potentially offering a non-surgical option for symptom management.

Standard Treatments vs. Investigational Approaches in Uterine Fibroid Trials

Approach	Examples	Typical Use Case	Limitations
Watchful waiting / Symptom management	Pain relief, iron supplements, hormonal contraceptives	Mild symptoms, small fibroids	Does not shrink fibroids; symptoms may persist
GnRH agonists/antagonists	Leuprolide, elagolix	Pre-surgical shrinkage or short-term symptom relief	Side effects like hot flashes, bone loss with long use; temporary
Surgical options	Myomectomy, hysterectomy, uterine artery embolization	Large or symptomatic fibroids	Invasive; recovery time, fertility impact, recurrence risk
Investigational (Letrozole in PLUM)	Aromatase inhibitor (letrozole 2.5mg) vs placebo	Symptomatic fibroids in premenopausal women	Early data in this specific trial; long-term effects and optimal use still under study

Note: This is for informational purposes only. Eligibility and outcomes are determined by the study team.

How Corterve Helps Patients Find Uterine Fibroid Trials

Corterve's platform matches patients to recruiting clinical trials using:

• Condition-specific search (e.g., "uterine fibroids," "leiomyoma," or "fibroid uterus").
• Location and travel radius filtering (California sites, Minnesota, Mississippi, North Carolina and beyond).
• Structured pre-screening based on age, imaging confirmation, symptom scores, menstrual history, and prior treatments.
• Direct referral to study sites when you pre-qualify.

Search actively recruiting uterine fibroid trials: Corterve Uterine Fibroids Trials

Get personalized alerts: Register with your ZIP code to be notified of new studies near you.

Questions to Ask Your Gynecologist or Study Team

• Is my fibroid size and symptom level appropriate for this letrozole trial or similar studies?
• What are the expected effects on fibroid size, bleeding, and fertility with letrozole?
• How does this compare to my current management plan or surgical options?
• What monitoring (imaging, labs, symptom tracking) is involved in the trial?
• Are there other open fibroid trials (e.g., new medications, non-hormonal options, or minimally invasive procedures) that might fit better?
• What are the potential side effects and follow-up requirements?

Important: Pre-qualification on Corterve is a first step only. The research site's team makes the final eligibility determination after full medical review, including exams, labs, and imaging. Uterine fibroid treatment decisions should always be made with your gynecologist or healthcare provider.

Disclaimer: Corterve is a clinical trial matching platform, not a medical provider. We do not give medical advice, diagnose conditions, or guarantee trial eligibility or outcomes. All eligibility determinations and medical decisions are made by the study's research team and your healthcare providers. This post uses publicly available trial metadata for informational purposes only. Consult a qualified healthcare professional before considering any clinical trial or changing your treatment plan.